Director-Affiliated Fund Invests $5M in Whitehawk Therapeutics' Private Placement

summarizeSummary

A director-affiliated investment fund, Acuta Capital, invested $5.0 million in Whitehawk Therapeutics' private placement, acquiring 1.27 million shares at $3.92 each.

check_boxKey Events

• Significant Investment in PIPE

  Acuta Capital Partners, an entity affiliated with director Anupam Dalal, purchased 1,275,510 shares of Common Stock for $5.0 million in a private placement that closed on May 14, 2026.

• Director's Conviction

  The investment, made at $3.92 per share, signals strong confidence from a key insider and major shareholder in the company's valuation and future prospects.

• Increased Beneficial Ownership

  Following the transaction, Acuta Capital Partners and its affiliates, including Anupam Dalal, beneficially own 9.0% of Whitehawk Therapeutics' common stock.

• Part of Larger Financing

  This investment is part of the $87.5 million private placement equity financing announced on May 13, 2026, providing capital for the company's ADC pipeline.

auto_awesomeAnalysis

Acuta Capital Partners, an investment adviser whose manager Anupam Dalal is a director of Whitehawk Therapeutics, disclosed a $5.0 million investment in the company's recent private placement. This significant capital infusion, part of the previously announced $87.5 million PIPE financing, demonstrates strong conviction from a key insider and major shareholder, providing crucial funding for the company's strategic initiatives.